Prevalence and Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder Diagnoses Among US Transgender and Cisgender Adults | Adolescent Medicine | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Coulter  RW, Blosnich  JR, Bukowski  LA, Herrick  AL, Siconolfi  DE, Stall  RD.  Differences in alcohol use and alcohol-related problems between transgender- and nontransgender-identified young adults.   Drug Alcohol Depend. 2015;154:251-259. doi:10.1016/j.drugalcdep.2015.07.006PubMedGoogle ScholarCrossref
2.
Rowe  C, Santos  G-M, McFarland  W, Wilson  EC.  Prevalence and correlates of substance use among trans female youth ages 16-24 years in the San Francisco Bay Area.   Drug Alcohol Depend. 2015;147:160-166. doi:10.1016/j.drugalcdep.2014.11.023PubMedGoogle ScholarCrossref
3.
Reisner  SL, Biello  KB, White Hughto  JM,  et al.  Psychiatric diagnoses and comorbidities in a diverse, multicity cohort of young transgender women: baseline findings from project LifeSkills.   JAMA Pediatr. 2016;170(5):481-486. doi:10.1001/jamapediatrics.2016.0067PubMedGoogle ScholarCrossref
4.
Keuroghlian  AS, Reisner  SL, White  JM, Weiss  RD.  Substance use and treatment of substance use disorders in a community sample of transgender adults.   Drug Alcohol Depend. 2015;152:139-146. doi:10.1016/j.drugalcdep.2015.04.008PubMedGoogle ScholarCrossref
5.
Jun  H-J, Webb-Morgan  M, Felner  JK,  et al.  Sexual orientation and gender identity disparities in substance use disorders during young adulthood in a United States longitudinal cohort.   Drug Alcohol Depend. 2019;205:107619. doi:10.1016/j.drugalcdep.2019.107619PubMedGoogle Scholar
6.
James  SE, Herman  JL, Rankin  S, Keisling  M, Mottet  L, Anafi  M. The report of the 2015 U.S. Transgender Survey. Accessed January 4, 2021. http://www.ustranssurvey.org/report/
7.
Benotsch  EG, Zimmerman  R, Cathers  L,  et al.  Non-medical use of prescription drugs, polysubstance use, and mental health in transgender adults.   Drug Alcohol Depend. 2013;132(1-2):391-394. doi:10.1016/j.drugalcdep.2013.02.027PubMedGoogle ScholarCrossref
8.
Reisner  SL, White  JM, Bradford  JB, Mimiaga  MJ.  Transgender health disparities: comparing full cohort and nested matched-pair study designs in a community health center.   LGBT Health. 2014;1(3):177-184. doi:10.1089/lgbt.2014.0009PubMedGoogle ScholarCrossref
9.
Reisner  SL, Pardo  ST, Gamarel  KE, White Hughto  JM, Pardee  DJ, Keo-Meier  CL.  Substance use to cope with stigma in healthcare among U.S. female-to-male trans masculine adults.   LGBT Health. 2015;2(4):324-332. doi:10.1089/lgbt.2015.0001PubMedGoogle ScholarCrossref
10.
White Hughto  JM, Pachankis  JE, Willie  TC, Reisner  SL.  Victimization and depressive symptomology in transgender adults: the mediating role of avoidant coping.   J Couns Psychol. 2017;64(1):41-51. doi:10.1037/cou0000184PubMedGoogle ScholarCrossref
11.
Reisner  SL, Greytak  EA, Parsons  JT, Ybarra  ML.  Gender minority social stress in adolescence: disparities in adolescent bullying and substance use by gender identity.   J Sex Res. 2015;52(3):243-256. doi:10.1080/00224499.2014.886321PubMedGoogle ScholarCrossref
12.
McDowell  A, Progovac  AM, Cook  BL, Rose  S.  Estimating the health status of privately insured gender minority children and adults.   LGBT Health. 2019;6(6):289-296. doi:10.1089/lgbt.2018.0238PubMedGoogle ScholarCrossref
13.
Dragon  CN, Guerino  P, Ewald  E, Laffan  AM.  Transgender Medicare beneficiaries and chronic conditions: exploring fee-for-service claims data.   LGBT Health. 2017;4(6):404-411. doi:10.1089/lgbt.2016.0208PubMedGoogle ScholarCrossref
14.
Reisner  SL, White  JM, Mayer  KH, Mimiaga  MJ.  Sexual risk behaviors and psychosocial health concerns of female-to-male transgender men screening for STDs at an urban community health center.   AIDS Care. 2014;26(7):857-864. doi:10.1080/09540121.2013.855701PubMedGoogle ScholarCrossref
15.
McDuffie  E, Brown  GR.  70 US veterans with gender identity disturbances: a descriptive study.   Int J Transgenderism. 2010;12(1):21-30. doi:10.1080/15532731003688962Google ScholarCrossref
16.
Quinn  VP, Nash  R, Hunkeler  E,  et al.  Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people.   BMJ Open. 2017;7(12):e018121. doi:10.1136/bmjopen-2017-018121PubMedGoogle Scholar
17.
Blosnich  JR, Marsiglio  MC, Dichter  ME,  et al.  Impact of social determinants of health on medical conditions among transgender veterans.   Am J Prev Med. 2017;52(4):491-498. doi:10.1016/j.amepre.2016.12.019PubMedGoogle ScholarCrossref
18.
Brown  GR, Jones  KT.  Mental health and medical health disparities in 5135 transgender veterans receiving healthcare in the Veterans Health Administration: a case-control study.   LGBT Health. 2016;3(2):122-131. doi:10.1089/lgbt.2015.0058PubMedGoogle ScholarCrossref
19.
Valentine  SE, Shipherd  JC.  A systematic review of social stress and mental health among transgender and gender non-conforming people in the United States.   Clin Psychol Rev. 2018;66:24-38. doi:10.1016/j.cpr.2018.03.003PubMedGoogle ScholarCrossref
20.
Garofalo  R, Deleon  J, Osmer  E, Doll  M, Harper  GW.  Overlooked, misunderstood and at-risk: exploring the lives and HIV risk of ethnic minority male-to-female transgender youth.   J Adolesc Health. 2006;38(3):230-236. doi:10.1016/j.jadohealth.2005.03.023PubMedGoogle ScholarCrossref
21.
Flentje  A, Leon  A, Carrico  A, Zheng  D, Dilley  J.  Mental and physical health among homeless sexual and gender minorities in a major urban US city.   J Urban Health. 2016;93(6):997-1009. doi:10.1007/s11524-016-0084-3PubMedGoogle ScholarCrossref
22.
Jasuja  GK, de Groot  A, Quinn  EK,  et al.  Beyond gender identity disorder diagnoses codes: an examination of additional methods to identify transgender individuals in administrative databases.   Med Care. 2020;58(10):903-911. doi:10.1097/MLR.0000000000001362PubMedGoogle ScholarCrossref
23.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. Accessed January 4, 2021. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf
24.
Baskerville  NB, Dash  D, Shuh  A,  et al.  Tobacco use cessation interventions for lesbian, gay, bisexual, transgender and queer youth and young adults: a scoping review.   Prev Med Rep. 2017;6:53-62. doi:10.1016/j.pmedr.2017.02.004PubMedGoogle ScholarCrossref
25.
Drope  J, Liber  AC, Cahn  Z,  et al.  Who’s still smoking? disparities in adult cigarette smoking prevalence in the United States.   CA Cancer J Clin. 2018;68(2):106-115. doi:10.3322/caac.21444PubMedGoogle ScholarCrossref
26.
Schwindt  R, Elkhadragy  N, Hudmon  KS.  Tobacco-related health disparities in gender-diverse populations: a call to action.   Transgender Health. 2020;5(2):86-89. doi:10.1089/trgh.2019.0063Google ScholarCrossref
27.
US Centers for Disease Control and Prevention. Lesbian, gay, bisexual, and transgender persons and tobacco use. Reviewed November 25, 2019. Accessed December 10, 2020. https://www.cdc.gov/tobacco/disparities/lgbt/index.htm
28.
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health.  The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. US Centers for Disease Control and Prevention; 2014.
29.
Hser  Y-I, Mooney  LJ, Saxon  AJ,  et al.  High mortality among patients with opioid use disorder in a large healthcare system.   J Addict Med. 2017;11(4):315-319. doi:10.1097/ADM.0000000000000312PubMedGoogle ScholarCrossref
30.
US Centers for Disease Control and Prevention. Marijuana: how can it affect your health? US Department of Health and Human Services. Reviewed February 27, 2018. Accessed April 28, 2020. https://www.cdc.gov/marijuana/health-effects.html
31.
Budge  SL, Katz-Wise  SL, Tebbe  EN, Howard  KA, Schneider  CL, Rodriguez  A.  Transgender emotional and coping processes: facilitative and avoidant coping throughout gender transitioning.   Counseling Psychol. 2013;41(4):601-647. doi:10.1177/0011000011432753Google ScholarCrossref
32.
US Centers for Disease Control and Prevention. 2018 Annual surveillance report of drug-related risks and outcomes—United States. Published August 31, 2018. Accessed January 4, 2021. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
33.
Reisner  SL, White Hughto  JM, Pardee  D, Sevelius  J.  Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males.   Int J STD AIDS. 2016;27(11):955-966. doi:10.1177/0956462415602418PubMedGoogle ScholarCrossref
34.
Grant  BF, Shmulewitz  D, Compton  WM.  Nicotine use and DSM-IV nicotine dependence in the United States, 2001-2002 and 2012-2013.   Am J Psychiatry. 2020;177(11):1082-1090. doi:10.1176/appi.ajp.2020.19090900PubMedGoogle ScholarCrossref
35.
US Centers for Disease Control and Prevention. Table A-12a: age-adjusted percentages (with standard errors) of current cigarette smoking status among adults aged 18 and over, by selected characteristics: United States, 2018. Accessed December 10, 2020. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2018_SHS_Table_A-12.pdf
36.
Kviz  FJ, Clark  MA, Crittenden  KS, Warnecke  RB, Freels  S.  Age and smoking cessation behaviors.   Prev Med. 1995;24(3):297-307. doi:10.1006/pmed.1995.1048PubMedGoogle ScholarCrossref
37.
Kramarow  EA. Health of former cigarette smokers aged 65 and over: United States, 2018. Published July 22, 2020. Accessed January 4, 2021. https://stacks.cdc.gov/view/cdc/91791
38.
Reback  CJ, Fletcher  JB.  HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach.   AIDS Behav. 2014;18(7):1359-1367. doi:10.1007/s10461-013-0657-zPubMedGoogle ScholarCrossref
39.
Wolfe  HL, Biello  K, Reisner  SR, Mimiaga  MJ, Cahill  S, Hughto  JMW. Transgender-related discrimination and substance use, substance use disorder and treatment history in a multi-state sample of transgender adults. Paper presented at: American Public Health Association 2020; October 27, 2020; San Francisco, California.
40.
Wolf  EC, Dew  BJ.  Understanding risk factors contributing to substance use among MTF transgender persons.   J LGBT Issues Counseling. 2012;6(4):237-256. doi:10.1080/15538605.2012.727743Google ScholarCrossref
41.
McHugh  RK, Votaw  VR, Sugarman  DE, Greenfield  SF.  Sex and gender differences in substance use disorders.   Clin Psychol Rev. 2018;66:12-23. doi:10.1016/j.cpr.2017.10.012PubMedGoogle ScholarCrossref
42.
Lombardi  E.  Substance use treatment experiences of transgender/transsexual men and women.   J LGBT Health Res. 2007;3(2):37-47. doi:10.1300/J463v03n02_05PubMedGoogle ScholarCrossref
43.
Oberheim  ST, DePue  MK, Hagedorn  WB.  Substance use disorders (SUDs) in transgender communities: the need for trans-competent SUD counselors and facilities.   J Addict Offender Counseling. 2017;38(1):33-47. doi:10.1002/jaoc.12027Google ScholarCrossref
44.
Glynn  TR, van den Berg  JJ.  A systematic review of interventions to reduce problematic substance use among transgender individuals: a call to action.   Transgend Health. 2017;2(1):45-59. doi:10.1089/trgh.2016.0037PubMedGoogle ScholarCrossref
45.
Ali  MM, Teich  JL, Mutter  R.  Reasons for not seeking substance use disorder treatment: variations by health insurance coverage.   J Behav Health Serv Res. 2017;44(1):63-74. doi:10.1007/s11414-016-9538-3PubMedGoogle ScholarCrossref
46.
Brown  GR, Jones  KT.  Racial health disparities in a cohort of 5,135 transgender veterans.   J Racial Ethnic Health Disparities. 2014;1(4):257-266. doi:10.1007/s40615-014-0032-4Google ScholarCrossref
47.
Hughto  JMW, Pletta  D, Gordon  L, Cahill  S, Mimiaga  MJ, Reisner  SL.  Negative transgender-related media messages are associated with adverse mental health outcomes in a multistate study of transgender adults.   LGBT Health. 2020. doi:10.1089/lgbt.2020.0279PubMedGoogle Scholar
48.
Reisner  SL, Hughto  JM, Dunham  EE,  et al.  Legal protections in public accommodations settings: a critical public health issue for transgender and gender-nonconforming people.   Milbank Q. 2015;93(3):484-515. doi:10.1111/1468-0009.12127PubMedGoogle ScholarCrossref
49.
Todd  K, Peitzmeier  SM, Kattari  SK, Miller-Peruse  M, Sharma  A, Stephenson  R.  Demographic and behavioral profiles of nonbinary and binary transgender youth.   Transgend Health. 2019;4(1):254-261. doi:10.1089/trgh.2018.0068PubMedGoogle ScholarCrossref
50.
Reisner  SL, Hughto  JMW.  Comparing the health of non-binary and binary transgender adults in a statewide non-probability sample.   PLoS One. 2019;14(8):e0221583. doi:10.1371/journal.pone.0221583PubMedGoogle Scholar
51.
Sineath  RC, Woodyatt  C, Sanchez  T,  et al.  Determinants of and barriers to hormonal and surgical treatment receipt among transgender people.   Transgend Health. 2016;1(1):129-136. doi:10.1089/trgh.2016.0013PubMedGoogle ScholarCrossref
52.
Puckett  JA, Cleary  P, Rossman  K, Newcomb  ME, Mustanski  B.  Barriers to gender-affirming care for transgender and gender nonconforming individuals.   Sex Res Social Policy. 2018;15(1):48-59. doi:10.1007/s13178-017-0295-8PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Substance Use and Addiction
    February 4, 2021

    Prevalence and Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder Diagnoses Among US Transgender and Cisgender Adults

    Author Affiliations
    • 1Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island
    • 2Center for Health Promotion and Health Equity, Brown School of Public Health, Brown University, Providence, Rhode Island
    • 3Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island
    • 4Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts
    • 5RAND Corporation, Pittsburgh, Pennsylvania
    • 6School of Public Health, Hebrew University, Jerusalem, Israel
    • 7Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island
    • 8Center for Gerontology and Healthcare Research, Brown University, Providence, Rhode Island
    • 9Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Affairs Medical Center, Bedford, Massachusetts
    • 10Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts
    • 11OptumLabs, Eden Prairie, Minnesota
    JAMA Netw Open. 2021;4(2):e2036512. doi:10.1001/jamanetworkopen.2020.36512
    Key Points

    Question  What is the prevalence of substance use disorder diagnoses (SUDDs) among US transgender and cisgender adults?

    Findings  In this study of 15 637 transgender and 46 911 cisgender adults, transgender adults had a significantly higher prevalence of nicotine, alcohol, and drug SUDDs than cisgender adults.

    Meaning  In this study, transgender adults experienced elevated levels of SUDD relative to their cisgender peers, suggesting that effective, culturally tailored SUDD treatment interventions are warranted.

    Abstract

    Importance  Substance use disorders are a major source of morbidity and mortality in the United States. National data comparing the prevalence of substance use disorder diagnoses (SUDDs) among transgender and cisgender individuals are lacking in the United States.

    Objectives  To investigate the prevalence of SUDDs among transgender and cisgender adults and to identify within-group and between-group differences by age, gender, and geographic location.

    Design, Setting, and Participants  This cross-sectional study used the OptumLabs Data Warehouse to analyze deidentified claims from approximately 74 million adults aged 18 years or older enrolled in commercial or Medicare Advantage insurance plans in 2017. A total of 15 637 transgender adults were identified based on a previously developed algorithm using a combination of International Classification of Diseases, Tenth Revision (ICD-10) transgender-related diagnosis and procedure codes and sex-discordant hormone prescriptions. A cohort of 46 911 cisgender adults was matched to the transgender cohort in a 3:1 ratio based on age and geographic location.

    Main Outcomes and Measures  SUDDs, based on ICD-10 codes, were assessed overall and compared between transgender and cisgender cohorts and by geographic region (ie, Northeast, Midwest, South, and West); age groups (eg, 18-25, 26-30, 31-35 years), and gender (ie, transfeminine [TF; assigned male sex at birth, identify along feminine gender spectrum], transmasculine [TM; assigned female sex at birth, identify along masculine gender spectrum], male, and female).

    Results  In this study of 15 637 transgender adults (4955 [31.7%] TM) and 46 911 cisgender adults (23 664 [50.4%] female), most (8627 transgender adults [55.2%]; 25 882 cisgender adults [55.2%]) were aged between 18 and 40 years, and 6482 transgender adults (41.5%) and 19 446 cisgender adults (41.5%) lived in the South. Comparing transgender to cisgender groups, significant differences were found in the prevalence of a nicotine (2594 [16.6%] vs 2551 [5.4%]; P < .001), alcohol (401 [2.6%] vs 438 [0.9%]; P < .001), and drug (678 [4.3%] vs 549 [1.2%]; P < .001) SUDDs. Among transgender adults, cannabis was the most prevalent drug SUDD (321 [2.1%]), followed by opioid SUDD (205 [1.3%]) and cocaine SUDD (81 [0.5%]), whereas among cisgender adults, cannabis and opioid SUDDs were equally prevalent (cannabis, 186 [0.4%]; opioid, 207 [0.4%]), followed by cocaine SUDD (59 [0.1%]).

    Conclusions and Relevance  In this study, the prevalence of SUDDs was significantly elevated among transgender adults relative to their cisgender peers. These findings underscore the need for culturally tailored clinical interventions to treat substance use disorder in transgender populations.

    ×